Augmedix (AUGX) Stock Forecast, Price Target & Predictions
AUGX Stock Forecast
Augmedix stock forecast is as follows: an average price target of $2.67 (represents a 13.62% upside from AUGX’s last price of $2.35) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
AUGX Price Target
AUGX Analyst Ratings
Augmedix Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
May 14, 2024 | Brooks O'Neil | Loop Capital Markets | $3.50 | $1.15 | 204.35% | 48.94% |
May 14, 2024 | Yuan Zhi | B.Riley Financial | $3.00 | $2.34 | 28.21% | 27.66% |
May 14, 2024 | Elizabeth Anderson | Evercore ISI | $1.50 | $2.34 | -35.90% | -36.17% |
Apr 09, 2024 | Elizabeth Anderson | Evercore ISI | $5.00 | $4.02 | 24.38% | 112.77% |
Apr 03, 2024 | Yuan Zhi | B.Riley Financial | $5.50 | $4.02 | 36.82% | 134.04% |
Mar 19, 2024 | Elizabeth Anderson | Evercore ISI | $4.50 | $3.96 | 13.64% | 91.49% |
Augmedix Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 6 |
Avg Price Target | - | - | $3.83 |
Last Closing Price | $2.35 | $2.35 | $2.35 |
Upside/Downside | -100.00% | -100.00% | 62.98% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jul 19, 2024 | B. Riley | - | Neutral | Downgrade |
Jul 19, 2024 | William Blair | - | Market Perform | Downgrade |
Jun 04, 2024 | Lake Street | Buy | Buy | Hold |
May 14, 2024 | Lake Street | Buy | Buy | Hold |
Apr 09, 2024 | Evercore ISI | - | Outperform | Upgrade |
Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Augmedix Financial Forecast
Augmedix Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $12.68M | $11.77M | - | $9.63M | $8.75M | $7.86M | $7.33M | $6.99M | $6.58M | $5.63M | $5.17M |
Avg Forecast | $17.70M | $16.79M | $15.51M | $14.59M | $12.89M | $12.96M | $13.64M | $13.36M | $12.46M | $11.43M | $10.37M | $9.39M | $8.57M | $7.76M | $7.33M | $6.91M | $6.40M | $5.61M | $5.18M |
High Forecast | $17.70M | $16.79M | $15.51M | $14.59M | $12.89M | $13.07M | $13.64M | $13.36M | $12.46M | $11.43M | $10.37M | $9.39M | $8.57M | $7.76M | $7.33M | $6.91M | $6.40M | $5.61M | $5.18M |
Low Forecast | $17.70M | $16.79M | $15.51M | $14.59M | $12.89M | $12.83M | $13.64M | $13.36M | $12.46M | $11.43M | $10.37M | $9.39M | $8.57M | $7.76M | $7.33M | $6.91M | $6.40M | $5.61M | $5.18M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.03% | - | 1.03% | 1.02% | 1.01% | 1.00% | 1.01% | 1.03% | 1.00% | 1.00% |
Augmedix EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EBITDA | - | - | - | - | - | - | - | - | $-4.04M | $-4.40M | - | $-5.09M | $-5.44M | $-5.46M | $-6.05M | $-5.45M | $-5.45M | $-2.11M | $-3.87M |
Avg Forecast | $-13.30M | $-12.62M | $-11.65M | $-10.96M | $-9.68M | $-9.74M | $-10.25M | $-10.04M | $-9.36M | $-8.59M | $-7.79M | $-7.06M | $-6.44M | $-5.83M | $-5.51M | $-4.28M | $-4.81M | $-1.90M | $-3.89M |
High Forecast | $-13.30M | $-12.62M | $-11.65M | $-10.96M | $-9.68M | $-9.64M | $-10.25M | $-10.04M | $-9.36M | $-8.59M | $-7.79M | $-7.06M | $-6.44M | $-5.83M | $-5.51M | $-3.43M | $-4.81M | $-1.52M | $-3.89M |
Low Forecast | $-13.30M | $-12.62M | $-11.65M | $-10.96M | $-9.68M | $-9.83M | $-10.25M | $-10.04M | $-9.36M | $-8.59M | $-7.79M | $-7.06M | $-6.44M | $-5.83M | $-5.51M | $-5.14M | $-4.81M | $-2.28M | $-3.89M |
Surprise % | - | - | - | - | - | - | - | - | 0.43% | 0.51% | - | 0.72% | 0.85% | 0.94% | 1.10% | 1.27% | 1.13% | 1.11% | 0.99% |
Augmedix Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Net Income | - | - | - | - | - | - | - | - | $-4.49M | $-4.41M | - | $-5.27M | $-5.76M | $-5.52M | $-8.84M | $-6.43M | $-6.08M | $-2.86M | $-4.64M |
Avg Forecast | $-4.80M | $-5.87M | $-6.41M | $-6.94M | $-7.47M | $-7.21M | $-7.12M | $-6.94M | $-5.21M | $-6.14M | $-6.94M | $-8.01M | $-8.34M | $-9.21M | $-8.41M | $-5.09M | $-8.28M | $-2.57M | $-10.14M |
High Forecast | $-4.80M | $-5.87M | $-6.41M | $-6.94M | $-7.47M | $-7.21M | $-7.12M | $-6.94M | $-5.21M | $-6.14M | $-6.94M | $-8.01M | $-8.34M | $-9.21M | $-8.41M | $-4.07M | $-8.28M | $-2.06M | $-10.14M |
Low Forecast | $-4.80M | $-5.87M | $-6.41M | $-6.94M | $-7.47M | $-7.21M | $-7.12M | $-6.94M | $-5.21M | $-6.14M | $-6.94M | $-8.01M | $-8.34M | $-9.21M | $-8.41M | $-6.11M | $-8.28M | $-3.09M | $-10.14M |
Surprise % | - | - | - | - | - | - | - | - | 0.86% | 0.72% | - | 0.66% | 0.69% | 0.60% | 1.05% | 1.26% | 0.73% | 1.11% | 0.46% |
Augmedix SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
SG&A | - | - | - | - | - | - | - | - | $7.65M | $7.30M | - | $6.77M | $6.88M | $6.44M | $6.60M | $6.28M | $-7.92M | $5.39M | $4.95M |
Avg Forecast | $15.74M | $14.94M | $13.79M | $12.98M | $11.46M | $11.52M | $12.13M | $11.89M | $11.08M | $10.16M | $9.23M | $8.35M | $7.62M | $6.90M | $6.52M | $5.38M | $5.69M | $4.86M | $4.61M |
High Forecast | $15.74M | $14.94M | $13.79M | $12.98M | $11.46M | $11.63M | $12.13M | $11.89M | $11.08M | $10.16M | $9.23M | $8.35M | $7.62M | $6.90M | $6.52M | $6.46M | $5.69M | $5.83M | $4.61M |
Low Forecast | $15.74M | $14.94M | $13.79M | $12.98M | $11.46M | $11.41M | $12.13M | $11.89M | $11.08M | $10.16M | $9.23M | $8.35M | $7.62M | $6.90M | $6.52M | $4.30M | $5.69M | $3.88M | $4.61M |
Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.72% | - | 0.81% | 0.90% | 0.93% | 1.01% | 1.17% | -1.39% | 1.11% | 1.07% |
Augmedix EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
EPS | - | - | - | - | - | - | - | - | $-0.09 | $-0.10 | - | $-0.14 | $-0.15 | $-0.15 | $-0.24 | $-0.17 | $-0.16 | $-0.11 | $-0.17 |
Avg Forecast | $-0.09 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.14 | $-0.13 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.15 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.15 | $-0.14 | $-0.19 |
High Forecast | $-0.09 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.14 | $-0.13 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.15 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.15 | $-0.14 | $-0.19 |
Low Forecast | $-0.09 | $-0.11 | $-0.12 | $-0.13 | $-0.14 | $-0.14 | $-0.13 | $-0.13 | $-0.10 | $-0.12 | $-0.13 | $-0.15 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.15 | $-0.14 | $-0.19 |
Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.84% | - | 0.93% | 0.96% | 0.87% | 1.52% | 1.11% | 1.03% | 0.76% | 0.89% |
Augmedix Peer Comparison by Price Target
AUGX Forecast FAQ
Is Augmedix a good buy?
No, according to 5 Wall Street analysts, Augmedix (AUGX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of AUGX's total ratings.
What is AUGX's price target?
Augmedix (AUGX) average price target is $2.67 with a range of $1.5 to $3.5, implying a 13.62% from its last price of $2.35. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Augmedix stock go up soon?
According to Wall Street analysts' prediction for AUGX stock, the company can go up by 13.62% (from the last price of $2.35 to the average price target of $2.67), up by 48.94% based on the highest stock price target, and down by -36.17% based on the lowest stock price target.
Can Augmedix stock reach $4?
AUGX's average twelve months analyst stock price target of $2.67 does not support the claim that Augmedix can reach $4 in the near future.
What are Augmedix's analysts' financial forecasts?
Augmedix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $52.84M (high $52.96M, low $52.71M), average EBITDA is $-39.708M (high $-39.612M, low $-39.797M), average net income is $-28.74M (high $-28.74M, low $-28.74M), average SG&A $47M (high $47.11M, low $46.89M), and average EPS is $-0.538 (high $-0.538, low $-0.538). AUGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.59M (high $64.59M, low $64.59M), average EBITDA is $-48.538M (high $-48.538M, low $-48.538M), average net income is $-24.024M (high $-24.024M, low $-24.024M), average SG&A $57.45M (high $57.45M, low $57.45M), and average EPS is $-0.45 (high $-0.45, low $-0.45).
Did the AUGX's actual financial results beat the analysts' financial forecasts?
Based on Augmedix's last annual report (Dec 2023), the company's revenue was $44.86M, beating the average analysts forecast of $43.65M by 2.76%. Apple's EBITDA was $-17.681M, missing the average prediction of $-32.803M by -46.10%. The company's net income was $-19.171M, missing the average estimation of $-26.293M by -27.09%. Apple's SG&A was $29.13M, missing the average forecast of $38.83M by -24.98%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.493 by -10.66%. In terms of the last quarterly report (Dec 2023), Augmedix's revenue was $12.68M, beating the average analysts' forecast of $12.46M by 1.77%. The company's EBITDA was $-4.041M, missing the average prediction of $-9.363M by -56.84%. Augmedix's net income was $-4.491M, missing the average estimation of $-5.205M by -13.72%. The company's SG&A was $7.65M, missing the average forecast of $11.08M by -30.95%. Lastly, the company's EPS was $-0.0916, missing the average prediction of $-0.0975 by -6.05%